» LEARN ABOUT COVID-19 VARIANTS, VACCINES, TESTING, & VISITOR REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

NRG-BN003

Trial

Clinical Trial Title

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Trial Status

Open to Enrollment

Start Date

October 25, 2017

Location

Doctors & Locations

Trial Type

Cancer - Adult Oncology

Specific Condition

Grade II Meningioma

Description

This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.

Eligibility Criteria

  • Histologically confirmed diagnosis of WHO grade II meningioma confirmed by central pathology review
  • Age ≥ 18
  • Post-operative Zubrod Performance Status 0-1 within 60 days
  • History/physical examination, including neurologic examination within 60 days
  • If the patient is a woman is of childbearing potential, a serum pregnancy test, obtained within 14 days
     

Ineligibility Criteria

  • Optic nerve sheath meningioma, spinal or other extracranial meningioma, multiple meningiomas, hemangiopericytoma
  • Definitive evidence of metastatic meningioma
  • Prior invasive malignancy unless disease free for a minimum of 3 years
  • Previous radiotherapy to the scalp, cranium, brain, or skull base and radiation-induced meningiomas

  • Inability to undergo MRI with and without contrast

Please contact Legacy Oncology Research for additional study inclusion/exclusion information

 

IRB Number

Central IRB

Notes

https://clinicaltrials.gov/ct2/show/NCT03180268

Principal Investigator Name

Andrew Kee, MD

Contact Name

Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Contact E-Mail

oncologyresearch@lhs.org

Last Updated: Wednesday, January 27, 2021 12:56:50 PM